Kristina M. Hellman

Array ( [id] => 19343630 [patent_doc_number] => 20240252593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-01 [patent_title] => ASSESSING AND TREATING OBESITY [patent_app_type] => utility [patent_app_number] => 18/562949 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34770 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17843770 [patent_doc_number] => 11433112 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-09-06 [patent_title] => Collagen peptide-based medicament compositions and devices and methods of production and use thereof [patent_app_type] => utility [patent_app_number] => 17/749729 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 19119 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18177205 [patent_doc_number] => 20230037934 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => INSULIN GLARGINE/LIXISENATIDE FIXED RATIO FORMULATION [patent_app_type] => utility [patent_app_number] => 17/731371 [patent_app_country] => US [patent_app_date] => 2022-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65121 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17731371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790301 [patent_doc_number] => 20220249392 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => SURFACTANT PEPTIDE NANOSTRUCTURES AND USES THEREOF IN DRUG DELIVERY [patent_app_type] => utility [patent_app_number] => 17/722357 [patent_app_country] => US [patent_app_date] => 2022-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17722357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673004 [patent_doc_number] => 20230310467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => PHARMACEUTICAL COMBINATION THERAPY AND PREVENTION WITH APROTININ + REMDESIVIR OF SARS-CoV-2 AND/OR DISEASE ASSOCIATED WITH THIS INFECTION, INCLUDI COVID-19 [patent_app_type] => utility [patent_app_number] => 17/709609 [patent_app_country] => US [patent_app_date] => 2022-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6343 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17709609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20279405 [patent_doc_number] => 20250304647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-02 [patent_title] => Use Of Long-Acting Growth Hormone For Treating Inflammation-Induced Diseases [patent_app_type] => utility [patent_app_number] => 18/552656 [patent_app_country] => US [patent_app_date] => 2022-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18552656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17881194 [patent_doc_number] => 20220296671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING [patent_app_type] => utility [patent_app_number] => 17/680842 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680842 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595337 [patent_doc_number] => 20220144910 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => DOSING FOR PREVENTION OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) WITH IL-22 Fc FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/583891 [patent_app_country] => US [patent_app_date] => 2022-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 268514 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17583891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17748262 [patent_doc_number] => 20220226465 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => Coronavirus Immunogenic Compositions, Methods and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/648283 [patent_app_country] => US [patent_app_date] => 2022-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 106139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17648283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413155 [patent_doc_number] => 11667688 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Glucagon derivative and a composition comprising a long acting conjugate of the same [patent_app_type] => utility [patent_app_number] => 17/576519 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 17722 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462477 [patent_doc_number] => 20240316146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => METHODS OF REDUCING NEUROPATHY AND NEUROPATHIC SYMPTOMS AND TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/260677 [patent_app_country] => US [patent_app_date] => 2022-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37083 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -121 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18260677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411799 [patent_doc_number] => 12077606 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Cyclic peptide analogs and conjugates thereof [patent_app_type] => utility [patent_app_number] => 17/560105 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 39009 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 461 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17560105 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938189 [patent_doc_number] => 20240033328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => ACTH IN THE TREATMENT OF AN ADRENOCORTICOTROPIC HORMONE RESPONSIVE PEDIATRIC DISORDER [patent_app_type] => utility [patent_app_number] => 18/257500 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18257500 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19425082 [patent_doc_number] => 12084485 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-10 [patent_title] => Long acting glucagon like polypeptide-1 (GLP-1) receptor agonists and methods of use [patent_app_type] => utility [patent_app_number] => 17/553381 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 12 [patent_no_of_words] => 52770 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 277 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19601087 [patent_doc_number] => 20240391967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => METHODS AND USES FOR NDFIP1 FUSION POLYPEPTIDES IN TREATING NEURODEGENERATIVE DISEASES, BRAIN AND/OR TRAUMATIC AND NON-TRAUMATIC SPINAL CORD INJURIES, AND/OR OPTIC NEUROPATHIES [patent_app_type] => utility [patent_app_number] => 18/255136 [patent_app_country] => US [patent_app_date] => 2021-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13233 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17790581 [patent_doc_number] => 20220249672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => Protection and Delivery of Multiple Therapeutic Proteins [patent_app_type] => utility [patent_app_number] => 17/533958 [patent_app_country] => US [patent_app_date] => 2021-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17533958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657083 [patent_doc_number] => 20220177548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => Methods and Compositions for Treating Melanoma [patent_app_type] => utility [patent_app_number] => 17/533095 [patent_app_country] => US [patent_app_date] => 2021-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13605 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17533095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18664870 [patent_doc_number] => 11771735 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-03 [patent_title] => Composition for improving or preventing nonalcoholic fatty liver [patent_app_type] => utility [patent_app_number] => 17/530609 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 11 [patent_no_of_words] => 3567 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609924 [patent_doc_number] => 20220152203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => BROAD-BASED THERAPEUTIC FOR INACTIVATING COVID-19 AND OTHER VIRAL PATHOGENS USING CHEMILUMINESCENCE-ACTIVATED COMPOUNDS ENCAPSULATED IN NANOPARTICLES [patent_app_type] => utility [patent_app_number] => 17/526693 [patent_app_country] => US [patent_app_date] => 2021-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17526693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20256113 [patent_doc_number] => 12428456 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-30 [patent_title] => Peptide directed protein knockdown [patent_app_type] => utility [patent_app_number] => 17/520015 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 48 [patent_no_of_words] => 16341 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17520015 [rel_patent_id] =>[rel_patent_doc_number] =>)